Trexquant Investment LP Increases Stock Position in Celcuity, Inc. $CELC

Trexquant Investment LP grew its stake in shares of Celcuity, Inc. (NASDAQ:CELC) by 131.3% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 26,920 shares of the company’s stock after buying an additional 15,280 shares during the period. Trexquant Investment LP owned 0.07% of Celcuity worth $272,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Focus Financial Network Inc. purchased a new stake in Celcuity during the 1st quarter worth $108,000. Perkins Capital Management Inc. purchased a new stake in Celcuity during the 1st quarter worth $115,000. GAMMA Investing LLC boosted its position in Celcuity by 1,237.4% during the 1st quarter. GAMMA Investing LLC now owns 1,324 shares of the company’s stock worth $131,000 after purchasing an additional 1,225 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in Celcuity during the 4th quarter worth $142,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in Celcuity during the 4th quarter worth $167,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

Celcuity Stock Performance

NASDAQ:CELC opened at $60.77 on Wednesday. The company has a debt-to-equity ratio of 2.24, a current ratio of 4.58 and a quick ratio of 4.58. The firm has a 50-day moving average of $36.26 and a two-hundred day moving average of $19.56. The stock has a market cap of $2.58 billion, a P/E ratio of -17.61 and a beta of 0.72. Celcuity, Inc. has a 1-year low of $7.57 and a 1-year high of $63.06.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.14). On average, research analysts expect that Celcuity, Inc. will post -2.62 earnings per share for the current fiscal year.

Insider Activity at Celcuity

In other news, Director David Dalvey sold 100,000 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $43.98, for a total transaction of $4,398,000.00. Following the transaction, the director owned 125,000 shares of the company’s stock, valued at approximately $5,497,500. This trade represents a 44.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 15.78% of the company’s stock.

Analysts Set New Price Targets

CELC has been the subject of a number of research reports. Leerink Partners upped their price target on shares of Celcuity from $28.00 to $60.00 and gave the stock an “outperform” rating in a research report on Monday, July 28th. Needham & Company LLC decreased their price target on shares of Celcuity from $74.00 to $70.00 and set a “buy” rating for the company in a research report on Friday, August 15th. HC Wainwright upped their price target on shares of Celcuity from $50.00 to $66.00 and gave the stock a “buy” rating in a research report on Monday, August 18th. Finally, Stifel Nicolaus began coverage on shares of Celcuity in a research report on Tuesday, July 1st. They set a “buy” rating and a $30.00 price target for the company. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $56.50.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.